PTHLH and cancer: Non‐injected bone (no cancer cells) is not statistically significantly affected by anti‐PTHrP mAb treatment in terms of osteoblast numbers/mm2 (1.875 ± 0.211 for anti‐PTHrP mAb treatment versus 1.813 ± 0.181 for control IgG, n = 8, p = 0.989) or osteoclast numbers/mm2 (1.577 ± 0.233 for anti‐PTHrP mAb treatment versus 1.445 ± 0.077 for control IgG, n = 8, p = 0.474), or bone volume/total volume (BV/TV: 41.5% ± 1.3% for anti‐PTHrP mAb treatment versus 39.8% ± 1.2% for control IgG, n = 7 p = 0.338).